SANTA CLARA, Calif., 2017-11-21 14:00 CET (GLOBE NEWSWIRE) --
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International
(TWSE: ticker 6554) and a global drug discovery and development services
company providing translational platforms to advance oncology, inflammation,
cardiovascular and metabolic disease research, announces the publication of two
new papers. These joint publications illustrate the utility of Crown
Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes
in preclinical studies.
The research conducted by Crown Bioscience, Eli Lilly and Company and Ball
State University was published in two PLOS ONE papers:
-- Peterson et al. Glucose dysregulation and response to common anti-diabetic
agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856,
https://doi.org/10.1371/journal.pone.0179856
-- Droz et al. Correlation of disease severity with body weight and high fat
diet in the FATZO/Pco model PLOS One 2017;12(6):e0179808,
https://doi.org/10.1371/journal.pone.0179808
The FATZO model mirrors human disease conditions by providing polygenic obesity
and metabolic patterns of hyperglycemia and hyperinsulinemia to support insulin
resistance similar to the metabolic disease in patients with insulin resistance
/ type 2 diabetes.
"Crown Bioscience is committed to validating the translatability of our models
and providing novel scientific advancements that are representative of human
conditions of obesity and type 2 diabetes," said Jim Wang, Sr. Vice President,
Cardiovascular Metabolic Research, Crown Bioscience. "Our innovations will
continue to enable breakthroughs for preclinical drug discovery and
development."
For more information on Crown Bioscience's commitment to furthering the field
of cardiovascular and metabolic drug discovery, visit
https://www.crownbio.com/cvmd.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology, inflammation,
cardiovascular and metabolic disease research. With an extensive portfolio of
relevant models and predictive tools, Crown Bioscience enables clients to
deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing@crownbio.com© 2017 GlobeNewswire
